Bone Growth Stimulators Market - By Type (Bone Growth Stimulation Devices, Bone Morphogenetic Proteins (BMP), Platelet-Rich Plasma (PRP)), By Application (Spinal Fusion Surgeries, Delayed Union & Non-union Bone Fractures), By End-use & Forecast, 2022-2028

Bone Growth Stimulators Market - By Type (Bone Growth Stimulation Devices, Bone Morphogenetic Proteins (BMP), Platelet-Rich Plasma (PRP)), By Application (Spinal Fusion Surgeries, Delayed Union & Non-union Bone Fractures), By End-use & Forecast, 2022-2028

Bone Growth Stimulators Market Size

Bone Growth Stimulators Market size exceeded USD 875 million in 2021 and is estimated to register over 6.8% CAGR between 2022 and 2028. The increasing awareness regarding the availability of innovative bone growth stimulation treatment procedures among patient with bone and joint disorders is contributing to the overall market revenue.
 

In high-income nations, orthopedic diseases have long been the leading cause of death and disability. As American Bone Health (ABH) recognizes these disease conditions to be of primary importance, various government and non-government bodies are coming forth with awareness programs.
 

For instance, the International Osteoporosis Foundation (IOF) is actively operating to improve the awareness related to effective diagnosis and treatment of osteoporosis and related musculoskeletal diseases. Thus, supportive initiatives for driving awareness regarding these disease conditions are further expected to render significant impact, driving the bone growth stimulators industry growth.
 

Bone growth stimulators are intended to enhance the growth of bone tissue or fracture healing process in the condition of delay or failure. These devices are either external or surgically implanted into the area of the affected bone. It is a form of treatment that is used to boost the healing of nonunion fractures that refers to a bone fracture. These products comprise bone growth stimulation devices, bone morphogenetic proteins (BMP), and platelet-rich plasma (PRP). It provides medical professionals with a powerful tool in spinal fusion surgeries and other related procedures.
 

However, the high treatment cost associated with the bone morphogenetic proteins (BMP) is amongst the major factors hampering the bone growth stimulators market growth. The high cost of these treatment options hinders their adoption rate, especially in emerging markets.
 

For instance, as per the article published by the Journal of Neurosurgery, in 2019, the direct cost of bone morphogenetic proteins was USD 10,444. In low-middle income countries, such a high treatment cost of bone morphogenetic protein prohibits most of the practitioners from opting for the treatment. In the short run, this cost will be a major factor restricting bone growth stimulators industry expansion. However, in the long run, it will not have a very significant impact as the manufacturers innovate to make their products increasingly affordable.
 

The COVID-19 outbreak arose as an unparalleled health concern affecting the global industrial sectors, including the healthcare services and medical practices. The COVID-19 pandemic drastically promoted the disease burden and bundled the healthcare systems with a high influx of coronavirus infected patients, thereby hampering other medical services.
 

The modified standard operating protocols revised by the regulatory authorities, integrating social distancing norms have hampered the daily operations of many healthcare services, including bone growth stimulation treatment procedures. These developments led to suspension or postponing of the routine care by the majority of the healthcare facilities and only catering to the emergency requirements. For instance, certain orthopedic societies published recommendations regarding postponing elective orthopedic procedures, further negatively impacting the market revenue in early 2020.
 

Although, the COVID-19 pandemic fuelled the need for these products in home care settings. Technological developments and the incorporation of telemedicine in these treatments has increased treatment compliance and promoted the acceptance of bone growth stimulators positively. Also, among COVID-19 infected patients, joint diseases comprising rheumatoid arthritis were related to increased risk of infection and hospitalization owing to the iatrogenic effect of immunosuppressive agents comprising corticosteroids.
 

Thus, the postponed & delayed appointments along with the hampered practice of bone growth stimulation negatively impacted the industry demand in the initial phase of 2020; however, effective implementation of strategies to minimize associated risks of procedures among COVID-19 patients and surged demand for bone growth stimulators.
 

Growing incidence of bone and joint disorder is anticipated to amplify the market statistics

The incidence of bone and joint disorder is anticipated to proliferate industry growth in the coming years. The rapidly surging elderly population suffering from this disease condition has boosted the demand for spinal fusion surgeries and oral & maxillofacial surgeries that have further augmented the bone growth stimulators market growth positively. Joint disorders comprising osteoarthritis are considered to be one of the most prevalent diseases among people aged 65 years and above.
 

As per the Centers for Disease Control and Prevention (CDC), the prevalence of doctor-diagnosed arthritis is estimated to reach 78.4 million by 2040 in the U.S. According to the World Health Organization, in 2017, around 18% of women and 9.6% of men aged above 60 years had symptomatic osteoarthritis across the globe.
 

Similarly, as per the recent data, over 80% of individuals 40 years and above have lumbar spondylosis in the U.S. Bone growth stimulators operate to reduce intraosseous venous congestion and remodel bone, thereby offering multiple benefits for the treatment of such target diseases. As a result, this significant disease incidence is driving the industry growth positively.
 

Furthermore, orthopedic patients commonly have one or more risk factors comprising smoking, obesity, or diabetes that increase the chances of revision of a failed fusion. For such patients, post-surgical bone growth stimulation therapy has been investigated to significantly upsurge the probability of fusion success. As a result, the aforementioned factors will prove beneficial for the bone growth stimulators market expansion.
 

Bone Growth Stimulators Market Analysis

Based on type, the bone growth stimulators market is segmented into bone growth stimulation devices, bone morphogenetic proteins, and platelet-rich plasma therapy. The bone growth stimulation devices segment exceeded USD 437 million in 2021. This significant market share is primarily attributed to growing awareness in patients related to procedural assistance delivered by bone growth stimulation devices, growing technological advancements, etc.
 

The bone growth stimulation devices find wide applications in spinal fusion surgeries, non-union bone fractures, and maxillofacial surgeries among others. Surging technological advancements in these devices are stimulating the product adoption rate positively. These advancements in external & ultrasonic bone growth stimulators for accelerating the healing of indicated bone and several other breakthroughs have surged the procedure result and success rate.
 

Market players are focusing on research and development activities for developing innovative bone growth stimulation devices. For instance, Bioventus has introduced novel features in its Exogen bone healing system that enables the stimulation of the body’s natural healing process and reduces the risk of infection & complication. Thus, the above-mentioned variables are projected to significantly influence the industry landscape over the analysis period.
 

Based on application, the bone growth stimulators market is segmented as spinal fusion surgeries, delayed union & nonunion bone fractures, oral and maxillofacial surgeries, and others. The spinal fusion surgeries segment is expected to witness significant growth and reach more than USD 461 million by 2028. This dominant business share is owing to the growing adoption rate of minimally invasive spinal surgeries, rising incidences of obesity & degenerative spinal conditions, etc.
 

As per the National Spinal Cord Injury Statistical Center (NSCISC), the annual incidence of spinal cord injury (SCI) is around 54 cases per 1 million individuals in the U.S. According to the National Center for Biotechnology Information article published in 2021, between 250,000 - 500,000 patients suffer from a spinal cord injury each year worldwide. These statistics are expected to boost the segmental revenue significantly.
 

Further, the growing prevalence of such spinal conditions has led to a rise in surgical procedures, thereby augmenting the demand for minimally invasive treatment integrating the use of bone growth stimulators. The implementation of these product & services for spinal fusion surgeries offers better patient compliance as well as aids in delivering optimal outcomes. Thus, a host of capabilities possessed by bone growth stimulators is projected to augment the use of these product & services in spinal fusion surgeries, thereby driving the business scenario.
 

Based on end-use, the bone growth stimulators market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals segment is poised to reach more than USD 743 million by 2028. This high market share is majorly attributed to the growing patient preference of hospitals for quality care and affordability. The availability of a broad range of orthopedic treatments incorporating advanced bone growth stimulators caters to the patient population is also contributing to the market expansion.
 

Hospitals are also emphasizing delivering different comprehensive programs with personalized and professional support in target disease management. Similarly, the growing adoption and launch of user-friendly and cost-effective bone growth stimulators for use in hospitals are the significant variables propelling the product demand.
 

Ongoing enhancements in hospital facilities comprising easy accessibility to board-certified surgeons and transparency about the quality of care are augmenting the segmental growth. As a result, the above-mentioned factors are expected to fuel the bone growth stimulators market revenue during the analysis timeframe.
 

U.S. bone growth stimulators market is anticipated to reach over USD 501 million by 2028. This majority market share is mainly attributed to numerous factors including high acceptance of advanced bone growth stimulators devices, rise in the incidence of bone diseases, and the presence of key manufacturers in the country among others. The high incidence of joint ailments such as osteoporosis, arthritis, and rheumatoid arthritis among others in the U.S. is set to prove conducive for the market growth.
 

As per the Centers for Disease Control and Prevention (CDC), in 2017–2018, the age-adjusted prevalence of osteoporosis was 12.6% among people aged 50 years and above in the U.S. These statistics are anticipated to fuel the adoption rate of bone growth stimulators in the country. Additionally, the prominent market players including Medtronic, Zimmer Biomet, and DJO Global is focusing to introduce novel products to deliver optimal operability for practitioners are expected to propel the reginal market statistics.
 

Bone Growth Stimulators Market Share

Some of the major industry players operating in the bone growth stimulators market are

• Zimmer biomet
• Orthofix
• DJO Global 

. These market players concentrate on strategic developments such as partnerships, new product launch & commercialization, vertical integration for business expansion. Furthermore, these players are heavily investing in R&D activities that enables them to innovative & capitalize on these products that further helps to garner maximum revenue in the market.
 

Recent industry developments

• In April 2021, Orthofix announced the exclusive license agreement to commercialize the Italy-based IGEA’s bone, soft tissue, and cartilage stimulator product portfolio in the U.S and Canada. This agreement helped the company to expand its bone growth therapies portfolio across multiple care settings.
   
• In March 2018, Orthofix announced the U.S. FDA and CE Mark approval for its PhysioStim, a bone growth stimulator. This device is designed for use with smartphones and other mobile devices that delivers a non-invasive treatment option for patients with nonunion fracture. This product approval strengthened the company’s position as a global innovator and increased its customer base.
   

Bone growth stimulators market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2028, for the following segments

Click here to Buy Section of this Report

By Type

• Bone Growth Stimulation Devices
  • Electrical Bone growth stimulators
    • Combined Magnetic Field (CMF) Devices
    • Capacitive Coupling (CC) Devices
    • Pulsed Electromagnetic Field (PEMF) Devices
  • Implanted Bone growth stimulators
  • Ultrasonic Bone growth stimulators
• Bone Morphogenetic Proteins (BMP)
• Platelet-Rich Plasma (PRP) Therapy

By Application

• Spinal Fusion Surgeries
• Delayed Union & Nonunion Bone Fractures
• Oral And Maxillofacial Surgeries
• Others

By End-use

• Hospitals
• Ambulatory Surgery Centers 
• Others

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
  • Australia  
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia